# Study Reveals California Adolescents Perceive Daily Cannabis Use as Less Harmful Than … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/study-reveals-california-adolescents-perceive-daily-cannabis-use-as-less-harmful-than/ > **Published:** 2026-05-15T08:33:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:06-04:00 > **Clinical Summary:** California study shows adolescent cannabis perception underestimates daily use harm. Clinical strategies to close perception gaps in primary care. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchSafetyPediatricsMental HealthPolicyTHCAnxiety Dr. Caplan’s Take “What I’m seeing in my practice is that adolescents who perceive cannabis as safer than benzodiazepines often haven’t developed the prefrontal cortex maturity to understand dose-response relationships or individual vulnerability to cannabis hyperemesis or psychotic breaks, yet they’re making decisions based on incomplete [risk assessment](https://cedclinic.com/ethical-legal-dilemmas-cannabis-use/). The real clinical challenge isn’t choosing between two imperfect options, it’s helping young patients understand that ‘less harmful than’ doesn’t mean ‘safe during critical neurodevelopmental windows.’” Clinical Perspective The perception gap between adolescents’ beliefs about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and actual developmental risks presents a significant challenge for clinical counseling in primary care and pediatric settings. Adolescent brains remain developmentally vulnerable to cannabinoids’ effects on cognition, memory, and motivation through the mid-20s, yet normalization of cannabis use—particularly daily consumption—may lead young patients to underestimate genuine harms when discussing [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) history. Clinicians should recognize that adolescents’ risk perception is shaped by peer influence, media exposure, and evolving legalization landscapes, factors that may not align with current neuroscience evidence. Given these perception-reality gaps, opportunistic screening conversations about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns warrant explicit, non-judgmental discussion of frequency thresholds and developmental impacts rather than assuming adolescent patients have internalized risks. Integrating straightforward education about neurodevelopmental vulnerability into routine preventive visits may help calibrate adolescent 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Study%20Reveals%20California%20Adolescents%20Perceive%20Daily%20Cannabis%20Use%20as%20Less%20Harmful%20Than%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D54580)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D54580)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Study%20Reveals%20California%20Adolescents%20Perceive%20Daily%20Cannabis%20Use%20as%20Less%20Harmful%20Than%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D54580)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 405 Items — March 12, 2026](https://cedclinic.com/alabama-medical-cannabis-sales-2026-spring-launch/) - [CED Digest: 392 Items — March 11, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://hempgazette.com/news/adolescent-cannabis-perceptions-harm-study/](https://hempgazette.com/news/adolescent-cannabis-perceptions-harm-study/) Further Reading Cannabis Policy Wire[Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Evidence Watch[CBD in Childhood Epilepsy: What the Evidence Actually Shows](https://cedclinic.com/cannabidiol-pediatric-epilepsy-dosing-2025-review/) Evidence Watch[What the Evidence Really Says About CBD for Children With Epilepsy](https://cedclinic.com/cbd-pediatric-epilepsy-drug-interactions-2025-review/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).